Delayed‐start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Introduction: Solanezumab is an anti‐amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease (AD). Its mechanism suggests the possibility of slowing the progression of AD. Methods: A possible disease‐modifying effect of solanezumab was assessed using a new statistical method including noninferiority testing. Performance differences were compared during the placebo‐controlled period with performance differences after the placebo patients crossed over to solanezumab in the delayed‐start period. Results: Noninferiority of the 14‐item Alzheimer's Disease Assessment Scale‐Cognitive subscale (ADAS‐Cog 14 ) and Alzheimer's Disease Cooperative Study Activities of Daily Living inventory instrumental items (ADCS‐iADL) differences was met through 132 weeks, indicating that treatment differences observed in the placebo‐controlled period remained, within a predefined margin, after the placebo group initiated solanezumab. Solanezumab was well tolerated, and no new safety concerns were identified. Discussion: The results of this secondary analysis show that the mild subgroup of solanezumab‐treated patients who initiated treatment early, at the start of the placebo‐controlled period, retained an advantage at most time points in the delayed‐start period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Self-citationPhase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370
Self-citationDoody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Cited by
Targeting protein aggregation for the treatment of degenerative diseases
Eisele, Y. S., Monteiro, C., Fearns, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4593 · Cited by 419
Targeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 370
Praet, J., Manyakov, N. V., Muchene, L., Mai, Z., Terzopoulos, V., de Backer, S., Torremans, A., Guns, P.-J., Van De Casteele, T., Bottelbergs, A., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0329-8 · Cited by 133
“disease-modifying treatments are expected to delay AD progression optimally when they are administered during the early stages of AD pathology [4].”
BackgroundWessels, A. M., Siemers, E. R., Yu, P., Andersen, S. W., Holdridge, K. C., Sims, J. R., Sundell, K., Stern, Y., Rentz, D. M., Dubois, B., et al. (2015) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2015.82 · Cited by 86
Self-citationAstrocytic transporters in Alzheimer's disease
Ugbode, C., Hu, Y., Whalley, B., Peers, C., Rattray, M., & Dallas, M. L. (2017) · Biochemical Journal · doi:10.1042/bcj20160505 · Cited by 25
Metadata
- Authors
- Liu‐Seifert, H., Siemers, E., Holdridge, K. C., Andersen, S. W., Lipkovich, I., Carlson, C., Sethuraman, G., Hoog, S., Hayduk, R., Doody, R., & Aisen, P.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2015-07-25
- Volume
- 1
- Issue
- 2
- Pages
- 111-121
- ISSN
- 2352-8737 (ISSN-L)
- OpenAlex
- W1921787609
- Cited by
- 48
- References
- 4
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delayed‐start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. https://app.cochat.ai/papers/10.1016/j.trci.2015.06.006
- The paper
- Liu‐Seifert, H., Siemers, E., Holdridge, K. C., Andersen, S. W., Lipkovich, I., Carlson, C., Sethuraman, G., Hoog, S., Hayduk, R., Doody, R., & Aisen, P. (2015). Delayed‐start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. Alzheimer's & Dementia: Translational Research & Clinical Interventions. https://doi.org/10.1016/j.trci.2015.06.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.